HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yasushi Yatabe Selected Research

Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)

1/2022Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Non-small Cell Lung Cancer PDX Models with Driver Genetic Alterations.
12/2021Molecular testing in stage I-III non-small cell lung cancer: Approaches and challenges.
11/2021Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA.
11/2021Phase II Study of Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage IIIA-B (Discrete N2) Non-small-cell Lung Cancer: SQUAT trial (WJOG 12119L).
11/2021Smoking History Predicts High Presence of TILs and Efficacy of PD-1 Blockade in PD-L1 Expression-negative Non-small Cell Lung Cancer Patients.
10/2021Canadian ROS proto-oncogene 1 study (CROS) for multi-institutional implementation of ROS1 testing in non-small cell lung cancer.
1/2021Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions.
1/2021Alectinib for Miliary Lung Metastasis in ALK-Positive Lung Adenocarcinoma.
9/2019Long-term complete response in a patient with postoperative recurrent ALK-rearranged lung adenocarcinoma treated with crizotinib: A case report.
1/2019Biopsy of palliative lesions following radiotherapy.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yasushi Yatabe Research Topics

Disease

158Neoplasms (Cancer)
11/2022 - 04/2002
94Lung Neoplasms (Lung Cancer)
11/2021 - 01/2002
58Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2022 - 04/2005
38Adenocarcinoma
11/2022 - 06/2002
27Adenocarcinoma of Lung
01/2022 - 06/2002
26Neoplasm Metastasis (Metastasis)
11/2021 - 01/2002
19Stomach Neoplasms (Stomach Cancer)
01/2021 - 07/2008
16Carcinoma (Carcinomatosis)
01/2022 - 09/2004
16Breast Neoplasms (Breast Cancer)
12/2019 - 05/2004
15Colorectal Neoplasms (Colorectal Cancer)
09/2021 - 07/2008
9Small Cell Lung Carcinoma (Small Cell Lung Cancer)
04/2021 - 04/2002
9Carcinogenesis
07/2013 - 01/2002
8Squamous Cell Carcinoma (Epidermoid Carcinoma)
05/2013 - 04/2004
7Lymphoma (Lymphomas)
08/2019 - 07/2004
6Malignant Mesothelioma
01/2022 - 03/2007
6Squamous Cell Carcinoma of Head and Neck
01/2021 - 11/2012
6Disease Progression
11/2017 - 01/2007
5Circulating Neoplastic Cells
09/2019 - 01/2014
4Lymphatic Metastasis
12/2021 - 11/2012
4Inflammation (Inflammations)
12/2018 - 05/2010
4Mesothelioma
01/2017 - 11/2008
4Mucinous Adenocarcinoma (Mucinous Carcinoma)
10/2015 - 01/2007
4Pancreatic Neoplasms (Pancreatic Cancer)
01/2013 - 01/2010
3Neuroendocrine Tumors (Neuroendocrine Tumor)
02/2022 - 01/2019
3Sarcoma (Soft Tissue Sarcoma)
01/2021 - 08/2010
3Ascites
01/2021 - 05/2012
3Residual Neoplasm
06/2018 - 05/2015
3Colonic Neoplasms (Colon Cancer)
01/2018 - 02/2010
3T-Cell Lymphoma (Lymphoma, T Cell)
01/2017 - 11/2007
3Ductal Carcinoma
03/2016 - 01/2007
3Small Cell Carcinoma
12/2009 - 08/2007

Drug/Important Bio-Agent (IBA)

60ErbB Receptors (EGF Receptor)IBA
12/2021 - 05/2004
43Tyrosine Kinase InhibitorsIBA
12/2021 - 10/2003
26Gefitinib (Iressa)FDA Link
11/2017 - 10/2003
20Biomarkers (Surrogate Marker)IBA
11/2021 - 06/2006
20Proteins (Proteins, Gene)FDA Link
11/2021 - 05/2004
17Anaplastic Lymphoma KinaseIBA
09/2019 - 10/2010
16Phosphotransferases (Kinase)IBA
02/2022 - 07/2004
13Pharmaceutical PreparationsIBA
02/2022 - 05/2007
12Trastuzumab (Herceptin)FDA Link
01/2021 - 03/2005
11DNA (Deoxyribonucleic Acid)IBA
01/2022 - 04/2002
11Biological ProductsIBA
04/2021 - 12/2004
10Erlotinib Hydrochloride (CP 358,774)FDA Link
11/2017 - 06/2006
8B7-H1 AntigenIBA
01/2022 - 07/2015
8RNA (Ribonucleic Acid)IBA
01/2022 - 12/2004
8NivolumabIBA
12/2021 - 10/2016
8Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
05/2011 - 04/2004
7Transcription Factors (Transcription Factor)IBA
01/2022 - 06/2002
7CrizotinibIBA
10/2021 - 08/2013
7AntibodiesIBA
01/2020 - 05/2010
7Estrogen ReceptorsIBA
12/2013 - 01/2007
6MucinsIBA
11/2022 - 05/2004
6ParaffinIBA
12/2021 - 04/2006
6alectinibIBA
01/2021 - 01/2016
6Cell-Free Nucleic AcidsIBA
06/2020 - 05/2016
6Cisplatin (Platino)FDA LinkGeneric
08/2017 - 06/2008
6Bevacizumab (Avastin)FDA Link
01/2017 - 02/2011
6MicroRNAs (MicroRNA)IBA
12/2015 - 06/2004
6EnzymesIBA
08/2010 - 01/2002
5Thyroid Nuclear Factor 1IBA
01/2022 - 04/2008
5Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
05/2021 - 07/2004
5human ERBB2 proteinIBA
08/2018 - 05/2011
5Messenger RNA (mRNA)IBA
08/2018 - 06/2008
5Docetaxel (Taxotere)FDA Link
11/2017 - 02/2010
4Monoclonal AntibodiesIBA
01/2022 - 07/2008
4Pemetrexed (MTA)FDA Link
10/2019 - 02/2011
4PlatinumIBA
08/2017 - 12/2015
4Aldehyde DehydrogenaseIBA
06/2016 - 04/2010
4Cetuximab (Erbitux)FDA Link
03/2016 - 07/2008
3Keratins (Keratin)IBA
01/2022 - 09/2004
3Immune Checkpoint InhibitorsIBA
01/2022 - 04/2016
3Formaldehyde (Formol)FDA Link
12/2021 - 01/2015
3osimertinibIBA
12/2021 - 09/2018
3AmylasesFDA Link
01/2021 - 01/2007
3ORALIT (ORS)IBA
01/2020 - 07/2013
3Cadherins (E-Cadherin)IBA
01/2018 - 03/2008
3lysyllysine (Lys-Lys)IBA
06/2016 - 04/2010
3glutamyl-glutamic acid (Glu-Glu)IBA
06/2016 - 08/2010
3LigandsIBA
04/2016 - 02/2008
3Progesterone Receptors (Progesterone Receptor)IBA
04/2016 - 01/2007
3Phenobarbital (Luminal)FDA Link
03/2016 - 12/2012
3Epidermal Growth Factor (EGF)IBA
01/2014 - 12/2012
3Folic Acid (Vitamin M)FDA LinkGeneric
03/2012 - 08/2007
3Irinotecan (Camptosar)FDA LinkGeneric
08/2011 - 07/2010
3Oncogene Proteins (Oncogene Protein)IBA
08/2011 - 11/2008
2pembrolizumabIBA
12/2021 - 11/2018

Therapy/Procedure

52Therapeutics
02/2022 - 08/2003
30Drug Therapy (Chemotherapy)
11/2021 - 04/2006
8Radiotherapy
11/2021 - 04/2006
6Immunotherapy
11/2021 - 04/2016
4Molecular Targeted Therapy
01/2022 - 01/2017
4Neck Dissection (Radical Neck Dissection)
01/2021 - 02/2006
4Lymph Node Excision (Lymph Node Dissection)
12/2019 - 04/2013
4Mastectomy (Mammectomy)
01/2019 - 01/2007
4Combination Drug Therapy (Combination Chemotherapy)
03/2015 - 07/2010
3Precision Medicine
01/2022 - 05/2014
3Adjuvant Chemotherapy
12/2021 - 04/2012
3Neoadjuvant Therapy
01/2020 - 02/2014
3Radiofrequency Ablation
12/2018 - 08/2016
2Lasers (Laser)
01/2022 - 06/2007